Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on G-CSF (Nov 2017)

Posted by Matt Breese on Nov 19, 2017

According to our recent payer coverage analysis for G-CSF treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Payer, Branding & Marketing

Trends That Matter for Chronic Heart Failure

Posted by Matt Breese on Nov 16, 2017

Heart failure is one of the most common causes of patient hospitalization in the U.S. However, the mechanisms behind this are not fully understood in the medical field. 

For providers treating patients with chronic heart failure, new technology could drastically improve the success of treatment. UCLA researchers have created a virtual model that can test pharmaceuticals based on patient scenarios to prevent adverse events.

Read More

Topics: Specialty, Market Access

Perspectives on Twitter Marketing

Posted by Matt Breese on Nov 14, 2017

If you follow social media trends, you've likely heard the news that Twitter recently increased its messaging limit to 280 characters. The Twitter product team made this change after noticing that 9% of English-language Tweets included exactly 140 characters, indicating that many users were editing the length of their messages.

What does this tech change have to do with pharma? This modification can help pharma marketers make sure their messages are compliant with FDA guidelines, according to Andrew Grojean, Social Media Manager at Intouch Solutions

Read More

Topics: Industry Trends, Branding & Marketing

Trends That Matter for Acne Treatment

Posted by Matt Breese on Nov 9, 2017

The global acne treatment market is growing, and experts predict it will continue to grow through 2021. According to a report published by CISION, this growth can be attributed to several factors including rising disposable income, unhealthy eating habits, and increasing awareness about acne treatment options. 

However, CISION also outlined some challenges in the market including, "The entry of generic drugs, safety issue regarding products and increasing acceptance of anti-acne treatments that hinder the growth of the market."

Read More

Topics: Industry Trends

MMIT Reality Check on Heart Failure (Nov 2017)

Posted by Matt Breese on Nov 7, 2017

According to our recent payer coverage analysis for chronic heart failure treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Payer, Branding & Marketing

Perspectives on Real-World Data

Posted by Matt Breese on Nov 7, 2017

The pharmaceutical industry has seen an explosion in the availability of real-world data in recent years. In the past, pharma companies mainly relied on data from clinical trials. Today, real-world data provides new insights and opportunities to assess a broader population.

This information is increasingly influencing healthcare decision-makers. However, data scientists must have the skills to sort through unstructured health data, analyze it, understand the big picture, and portray the data visually. 

Read More

Topics: Industry Trends, Data & Analytics

Trends That Matter for Pharma Manufacturing

Posted by Matt Breese on Nov 2, 2017

Cutting-edge manufacturers know the importance of embracing new technologies. Pharma manufacturers are beginning to invest more in robotics and analytics to improve the efficiency at their plants. 

Specifically, Sanofi, pharma company headquartered in France, is making substantial investments in the area of collaborative robotics. Sanofi's biologics plant in Geel, Belgium uses digital tools to reduce opportunities for errors in the manufacturing process.  

Read More

Topics: Industry Trends

Perspectives on Specialty Pharmacies

Posted by Matt Breese on Oct 31, 2017

The promising outlook on specialty drug growth and profitability is attracting new competitors to the market. According to Matthew Panos, Program Manager of Retail Specialty Solutions at McKesson, “Patients who take specialty medications typically have three to 11 additional prescriptions, making them valuable patients."

Parties that dispense specialty drugs include PBMs, health plans, chain stores, pharma wholesalers, hospital systems, physician practices and independent pharmacies.  

Read More

Topics: Specialty, Industry Trends

MMIT Reality Check on Dermatology: Acne (Oct 2017)

Posted by Matt Breese on Oct 30, 2017

According to our recent payer coverage analysis for dermatology-acne, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Payer, Branding & Marketing

Trends That Matter for Narcotic Pain Treatment

Posted by Matt Breese on Oct 26, 2017

The FDA's Opioids Action Plan was recently developed with the goals of reducing incidents of opioid abuse in the United States, while still ensuring patients with chronic pain have access to the treatments they need. 

By understanding the impact of these drugs in the real-world, the FDA is making changes that will make them harder to abuse. With these new guidelines, pharmaceutical manufacturers in the narcotic pain treatment space are prioritizing opioid products with abuse-deterrent properties.

Read More

Topics: Specialty, Market Access